Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: A mini review

Journal of Drug Targeting

Volumn 23, Issue 9, 2015, Pages 775-788

  Kulkarni, Abhijeet D ^a   Vanjari, Yogesh H ^a   Sancheti, Karan H ^a   Belgamwar, Veena S ^b   Surana, Sanjay J ^a   Pardeshi, Chandrakantsing V ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b RTM NAGPUR UNIVERSITY   (India)

Author keywords

Blood brain barrier; Brain blood ratio; Nanomedicines; Nanotechnology; Nasal drug delivery; Neurodegenerative disorders; Nose to brain; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CHITOSAN NANOPARTICLE; ENTACAPONE; GELATIN; LIPID; MONOAMINE OXIDASE B INHIBITOR; NANOCARRIER; PARKIN; POLYGLACTIN; POLYMER; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SOLID LIPID NANOPARTICLE; TOLCAPONE; ANTIPARKINSON AGENT; NANOPARTICLE;

CELL THERAPY; COGNITIVE DEFECT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TRANSPORT; GENE THERAPY; HUMAN; LEWY BODY; MENTAL DISEASE; MOTOR DYSFUNCTION; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; BIOLOGICAL MODEL; BRAIN; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE; PROCEDURES;

ADMINISTRATION, INTRANASAL; ANTIPARKINSON AGENTS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, NEUROLOGICAL; NANOMEDICINE; NANOPARTICLES; NOSE; PARKINSON DISEASE;

EID: 84944682523     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1020809     Document Type: Review

References (97)

1. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996;2:106-13.
2. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40:385-403.
3. Davis SS. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 1997; 15:217-24.
4. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005;108:193-214.
5. Pardeshi CV, Rajput PV, Belgamwar VS, et al. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul 2011; 29:103-14.
6. Chen J, Wang X, Wang J, et al. Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. Eur J Pharm Biopharm 2008;68:694-700.
7. Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res 2011;92: 408-14.
8. Ali J, Ali M, Baboota S. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010;10: 1644-53.
9. Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv 2014;5:709-33.
10. Flachenecker P. Epidemiology of neuro-immunological diseases. J Neurol 2006;253:2-8.
11. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007;32: 1054-82.
12. Cole NB, Murphy DD. The cell biology of alpha-synuclein: a sticky problem? Neuromol Med 2002;1:95-109.
13. Pardeshi CV, Belgamwar VS, Tekade AR, et al. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med 2013;24: 2101-15.
14. Modi G, Pillay V, Choonara YE, et al. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 2009;88:272-85.
15. Biddlestone-Thorpe L, Marchi N, Guo K, et al. Nanomaterialmediated CNS delivery of diagnostic and therapeutic agents. Adv Drug Deliv Rev 2012;64:605-13.
16. Gomes MJ, Neves J, Sarmento B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 2014;9:1757-69.
17. Brambilla D, Droumaguet BL, Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 2011;7:521-40.
18. Kanwar RJ, Sun X, Punj V, et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine 2012;8:399-414.
19. Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas 2012;73:45-51.
20. Braak H, Bohl JR, Muller CM, et al. Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21: 2042-51.
21. Linazasoro G. Potential applications of nanotechnologies to Parkinson's disease therapy. Parkinsonism Relat Disord 2008;14: 383-92.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
23. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:104-53.
24. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-6.
25. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40: 1513-17.
26. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988;45:260-2.
27. Mayeux R, Stern Y, Rosen J, et al. Depression, intellectual impairment and Parkinson disease. Neurology 1981;31: 645-50.
28. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:175-9.
29. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986;9:357-81.
30. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Rev 2000;31:236-50.
31. Lapper SR, Bolam JP. Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 1992;51:533-45.
32. Abercrombie ED, Zigmond MJ. Modification of central catecholaminergic systems by stress and injury: functional significance and clinical implications. In: Bloom EJ, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995.
33. Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res 1989;503:334-8.
34. Zaja-Milatovic S, Milatovic D, Schantz AM, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545-7.
35. Villalba RM, Verreault M, Smith Y. Spine loss in the striatum of MPTP treated monkeys. A correlation with the degree of striatal dopaminergic denervation. Exp Neurol 2009;215:220-7.
36. Gibb WR, Scott T, Lees AJ. Neuronal inclusions of Parkinson's disease. Mov Disord 1991;6:2-11.
37. Kuzuhara S, Mori H, Izumiyama N, et al. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 1998;75:345-53.
38. Fergusson J, Landon M, Lowe J, et al. Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett 1996;219:167-70.
39. Ii K, Ito H, Tanaka K, et al. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997;56: 125-31.
40. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000; 47:521-3.
41. New Insight into Parkinson's Disease-NIH Director's Blog. Available at: www.directorsblog.nih.gov [last accessed 19 Aug 2014].
42. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492-7.
43. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976;38:271-6.
44. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-5.
45. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
46. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392: 605-8.
47. Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science 2002;299:256-9.
48. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary earlyonset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-60.
49. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7.
50. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
51. Lim KL, Ng CH. Genetic models of Parkinson disease. Biochim Biophys Acta 2009;1792:604-15.
52. Jellinger KA. A critical reappraisal of current staging of Lewyrelated pathology in human brain. Acta Neuropathol 2008;116: 1-16.
53. Arai K, Kato N, Kashiwado K, et al. Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 2000; 296:171-3.
54. Choi P, Snyder H, Petrucelli L, et al. SEPT5-v2 is a parkin-binding protein. Brain Res Mol Brain Res 2003;117:179-89.
55. Staropoli JF, McDermott C, Martinat C, et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003;37: 735-49.
56. Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105:891-902.
57. Corti O, Hampe C, Koutnikova H, et al. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 2003; 12:1427-37.
58. Ko HS, von Coelln R, Sriram R, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 2005; 25:7968-78.
59. Ko HS, Kim SW, Sriram SR, et al. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 2006;281:16193-6.
60. An Y, Tang L, Jiang X, et al. A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of a-synuclein. Chemistry 2010;16:14439-46.
61. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007;64:1083-8.
62. Bjorklund T, Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim Biophys Acta 2009;1792:703-13.
63. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009; 1792:688-702.
64. Sahni JK, Doggui S, Ali J. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 2011;152: 208-31.
65. Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2009;6:144-52.
66. Banerjee T, Mitra S, Kumar Singh A, et al. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002;243:93-105.
67. Vyas SP, Khar RK. Targeted and controlled drug delivery: a novel carrier system. New Delhi: CBS Publishers; 2002.
68. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002;6: 319-27.
69. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19.
70. Tan SW, Billa N, Roberts CR. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf A 2010;372:73-9.
71. Wilson B, Samanta MK, Santhi K, et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008;1200:159-68.
72. Olivier JC. Drug targeting to brain with targeted nanoparticles. NeuroRx 2005;2:108-19.
73. Pathan SA, Iqbal Z, Zaidi SMA, et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009;3:71-89.
74. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013;10:957-72.
75. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57.
76. Dagenais C, Rousselle C, Pollack GM, et al. Development of an in situ mouse brain perfusion model and its application to mdr1a Pglycoprotein-deficient mice. J Cereb Blood Flow Metab 2000;20: 381-6.
77. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 2006;7:183-203.
78. Doran A, Obach RC, Smith BJ, et al. The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/1b knockout mouse model. Drug Metab Dispos 2005;33:165-74.
79. Maurer TS, DeBartolo DB, Tess DA, et al. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005;33:175-81.
80. Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Del 2006;3:463-78.
81. Ieva E, Trapani A, Cioffi N, et al. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal Bioanal Chem 2009;393:207-15.
82. Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Biopharm 2013;48:393-405.
83. Md S, Haque S, Fazil M, et al. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv 2014;11:827-42.
84. Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi: 10.3109/03639045.2014.991400.
85. Sharma S, Lohan S, Murthy RSR. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 2014;40: 869-78.
86. Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.907372.
87. Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012; 161:505-22.
88. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011;7:4169-76.
89. Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 2011;151:131-8.
90. Gambaryan PY, Kondrasheva IG, Severin ES, et al. Increasing the efficiency of Parkinson's disease treatment using a poly(lactic-coglycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol 2014;23:246-52.
91. Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriersmediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine 2014;10:755-64.
92. Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv 2013;20:47-56.
93. Pardeshi C, Rajput P, Belgamwar V, et al. Solid lipid based nanocarriers: an overview. Acta Pharm 2012;62: 433-72.
94. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008;8:1696-702.
95. Lawrence MJ, Rees GD. Microemulsion based media as a novel drug delivery system. Adv Drug Del Rev 2000;45: 89-121.
96. Kumar M, Pathak K. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 2009;35:387-95.
97. Mustafa G, Baboota S, Ahuja A, et al. Formulation development of chitosan coated intranasal ropinirole nanoemulsion for better management option of parkinson: an in vitro ex vivo evaluation. Curr Nanosci 2014;3:348-60.